Products - Multiple sclerosis | Topic | NICE

Showing 4 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy (TA1126)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 January 2026
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC